Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

Fig. 1

Patient disposition chart. Twenty-eight patients in the culmerciclib group (receiving other antitumor therapy [n = 4], voluntary ceasing treatment [n = 4], refusing visit [n = 6], withdrawal due to personal reasons [n = 4], subjective intolerabilities [n = 3], intolerable toxicities [n = 2], cancer pain [n = 5]) and three patients in the placebo group (receiving other antitumor therapy [n = 2] and withdrawal due to personal reason [n = 1] withdrew from the study

Back to article page